[ad_1]
American pharmaceutical companyPfizer announced that a final analysis of data from a clinical trial for a new coronavirus vaccine candidate developed jointly with Biontech in Germany showed a 95% chance of efficacy. We are ready to apply for an emergency license (US) from the US authorities within the week.
According to the announcement on the 18th by both companies, the vaccine is effective regardless of age group and race, and the trial involving about 44,000 people has not caused any serious safety problems so far.
Moderna also announced promising test results for its vaccine candidates this week, and the results are expected to be released by Astra Zeneca and the University of Oxford in the UK soon.
In an interview with Bloomberg Television, Biontech CEO Ugur Sahin explained that the company and Pfizer plan to apply to the US Food and Drug Administration (FDA) no later than the 20th. He also said that he had already applied. to the European Pharmaceutical Agency (EMA), which carries out successive examinations.
The CEO said that he “communicates with EMA by phone and documents almost every day,” and said: “Based on the positive data we got today, all regulators, such as the FDA and EMA, can do their best. I am I’m sure we’ll try to complete the exam as soon as possible. “
According to data from Pfizer and Biontech, 170 of the subjects were infected with the new corona. Eight of them were vaccinated and 162 were subjects vaccinated with fake drugs. The vaccine also helped prevent exacerbation, with 9 out of 10 critically ill patients in the fake drug group.
Data from Pfizer and Biontech show efficacy regardless of age group or race
The vaccine was effective in just over 94% of the elderly 65 years and older.
3.8% of those who received the second vaccine complained of severe discomfort, but most of the vaccinated people did not present physical changes.
Bamil Divan, an analyst at Mizuho Securities USA, said of the announcement: “It appears to be a very reasonable side reaction considering the benefits of the vaccine and showing the remarkable effect of the vaccine, I wrote in the report.
Pfizer and Biontech said last week that the vaccine was more than 90% effective.Interim results revealed. Pfizer CEO Albert Bula explained yesterday that he had collected the two-month safety monitoring data required by the FDA.
On the US stock market on the 18thPfizer shares temporarily rose 3.8% from the previous day.Biontech’s US deposit values (ADRs) were up 6.4% in some cases. The closing price was 0.8% higher for Pfizer and 4.0% higher for Biontech’s ADR.
Original title:Pfizer plans presented as a vaccine are 95% effective (2) （抜 粋）
(Biontech CEO comments will be added to paragraphs 4 and 5 to update)
